In vitro susceptibility of beta-lactamase producing Pseudomaonas aeruginosa isolates to antibiotics and essential oils
DOI:
https://doi.org/10.5457/ams.v50i1-2.542Keywords:
essential oils, Pseudomonas aeruginosa, beta-lactamase, antibiotic resistance, minimal inhibitory concentration (MIC)Abstract
Background: As antibiotic resistance in microorganisms is increasingand becoming a global problem, essential oils should be considered as new chemical substances with potenial therapeutic effects.
Aim of the study: Determine the susceptibility of beta-lactamase clinical isolates of Pseudomonas aeruginosa to antibiotics and essential oils, define the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for tested oils.
Material and Methods: This study included 120 P. aeruginosa isolates from clinical material. A disc diffusion method was used to for determination of antibiotic and essential oil susceptibility profile. For the phenotypic detection of beta-lactamase isolates, a disk diffusion method was used according to the CLSI guidelines with clavulanic acid. MIC was determined by microdilution test in broth. MBC was recorded after determination of MIC, it was corresponded to the lowest concentration of the essential oil yielding negative subcultures after incubation at appropriate temperature for 24 h.
Results: Of the three tested oils, Origanum compactum had the strongest antimicrobial effect (MIC 6.4 mg/ml - 9.3 mg / ml) on P. aeruginosa isolates followed by Thymus serpylum (MIC 13 mg / ml to 78 mg / ml) and Origanum majorana (MIC 21,5 mg/ml do 43 mg/ml ).
Conclusion: Beta-lactamase producing P. aeruginosa isolates resistant to third and forth genetration of cephalosporin antibiotics, showed susceptibility against tested essential oils.
Â
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
